Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights
11:26am, Saturday, 20'th Dec 2025
NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
Assenagon Asset Management S.A. Lowers Stake in Amicus Therapeutics, Inc. $FOLD
03:25am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 47.7% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional inv
Market Today: Oracle-TikTok JV, Tesla Pay Reinstated, Nike Sinks
05:35pm, Friday, 19'th Dec 2025
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play
12:41pm, Friday, 19'th Dec 2025
BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Amicus Therapeutics Inc. (FOLD) in a transaction valued at about $4.8 billion, a move that could stren
BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal
12:14pm, Friday, 19'th Dec 2025
BioMarin (BMRN) is acquiring Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash deal valued at approximately $4.8 billion. This acquisition, expecte
MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transacti
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
09:48am, Friday, 19'th Dec 2025
DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driv
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
09:26am, Friday, 19'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per s
BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal
09:03am, Friday, 19'th Dec 2025
BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
08:13am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
07:56am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Mi
Bradley Campbell Sells 77,926 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
04:44am, Friday, 19'th Dec 2025
Amicus Therapeutics, Inc. (NASDAQ: FOLD - Get Free Report) CEO Bradley Campbell sold 77,926 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an averag
Zacks Industry Outlook Arcutis, Amicus and ANI
04:46am, Thursday, 18'th Dec 2025
Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Watch for Potential Upside
03:21pm, Wednesday, 17'th Dec 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
